While consolidating its business in the developing world, Unichem is now set to emerge as a responsible global pharmaceutical organization by entering the developed countries. Unichem's strategy for growth is to leverage its competencies in R&D , manufacturing and business development to exploit the increasing opportunities presented by the generic segment in the developed markets like Europe and the US.

Unichem's International operations are divided into 3 distinct regions:

• European Union (EU)
• The Americas
• Zone I

European Union (EU):

Unichem's growing presence in the EU is driven through its joint venture with Niche generics, UK.

Niche specializes in the development, licensing and marketing of generics in the European Union.

Niche markets its products through its own livery in UK and Ireland and through marketing and licensing agreements in other European countries like Germany, France, Denmark and Sweden.

Unichem has also collaborated with other European partners for Product development and Co-marketing agreements

The Americas:

Unichem's foray into the Americas span the US, Canada and Latin America.

US:

As a keystone of its strategy for developed countries, Unichem has made significant progress in the US by signing product-specific agreements with leading generic companies like New Jersey based PLIVA Inc.** and Philadelphia based Lannett Company Inc.**. Our Product Development Centres in Goa and Mumbai in India are actively working on developing finished products for launch in the US market through these partnership arrangements.Unichem plans to file at least 8-10 ANDAs every year in the US.

Unichem Pharmaceuticals (USA), Inc., Unichem's wholly owned subsidiary , based in New Jersey is actively pursuing medium to long term business opportunities in the US , apart from ANDA filings on behalf of the parent company.

**PLIVA Inc. to market Unichem generics under join label in US markets.

**Agreement with LANNETT COMPANY, INC, USA, for exclusive supply of generic drugs.

Canada:

Unichem has joined hands with leading Canadian generic companies for Product development and Supply agreements.

Latam:

• Unichem's subsidiary company Unichem Farmaceutica do Brasil Ltda., will focus on the growing demand for generic products in the Brazilian pharmaceutical market. Unichem has set up its own infrastructure to develop its business in Brazil.
• In Central American region the focus will be on marketing Unichem's branded generics. Towards this Unichem has formed distribution and marketing alliances with the key players in many markets.

Zone I :

Zone I comprises of rest of the world excluding EU and the Americas. Unichem's strategy in Zone I is to focus on high value-added branded generics by leveraging its core competencies.

Unichem has full -fledged Representative offices in Kiev and Moscow and a liaison office in Ghana.

A subsidiary company in South Africa - Unichem SA (Pty) Ltd.- taps the potential existing in the South Africa market.

Besides this there is a network of distribution and marketing alliances in the SE Asian region, CIS, Eastern Europe, Middle East, Africa and in the SAARC countries.

To drive growth in these markets Unichem works with its own Sales and Marketing infrastructure and distribution alliances.